Abstract
In the last decade, improvements in both non-transplant and transplant therapy have extended the lives of patients with CML, particularly those in chronic phase. The future will probably bring a greater understanding of molecular leukaemogenesis and options for treating CML. Non-transplant therapies in development include novel agents and combination therapy. Transplant strategies seek to decrease regimen-related toxicity and directly manipulate the immune system to eradicate disease. Clinical and laboratory science seems poised to add novel therapies to the armamentarium against CML. It is exciting to contemplate what reviews of CML written 10 years from now will discuss.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Disease Progression
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Interferon Type I / therapeutic use
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / mortality
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / therapy
-
Leukemia, Myeloid, Chronic-Phase / genetics
-
Leukemia, Myeloid, Chronic-Phase / mortality
-
Leukemia, Myeloid, Chronic-Phase / therapy
-
Lymphocyte Activation
-
Philadelphia Chromosome
-
Randomized Controlled Trials as Topic
-
Recombinant Proteins
-
Recurrence
-
Risk
-
Survival Analysis
-
Transplantation, Homologous
-
Treatment Outcome
Substances
-
Interferon Type I
-
Recombinant Proteins